Lakewood-Amedex Biotherapeutics
Develops topical Nu-3 gel for mildly infected diabetic foot ulcers.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. Actinium Pharmaceuticals (NYSE:ATNM) Financial Contrast
Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Profitability This table compares Actinium Pharmaceuticals and
Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
Nu-3, a Phase 2-ready candidate targeting the treatment of infected diabetic foot ulcers (iDFU), targets disruption of bacterial membranes through a unique, physical mechanism of action and has demonstrated a high barrier to resistance. SARASOTA, Fla.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. MBX Biosciences (NASDAQ:MBX) Critical Survey
MBX Biosciences (NASDAQ: MBX - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation. Valuation and Earnings This table compares MBX Biosciences
Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
Nu-3 is a gel formulation of a Bisphosphocin® compound targeting the topical treatment of infected diabetic foot ulcers with low likelihood of producing systemic side effects. SARASOTA, Fla.
Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
Company highlights its differentiated Bisphosphocin ® platform and lead clinical candidate Nu-3 as innovative approaches to addressing microbial infections and the risk of resistance development SARASOTA, Fla., July 7, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, legislation designed to encourage the development of novel therapies to address the growing global threat of antimicrobial resistance (AMR).
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D.
Leading clinician and surgeon to also serve as Scientific Advisor for Lakewood-Amedex Biotherapeutics' iDFU program SARASOTA, Fla., June 25, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that David G.
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections
New patent enhances global IP footprint and pipeline expansion opportunities SARASOTA, Fla., June 22, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the expansion of the Company's patent portfolio with the issuance of a new patent in Australia protecting Bisphosphocin® compounds that are being explored in a range of antimicrobial infections including complicated urinary tract infections and pulmonary infections.
Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum
SARASOTA, Fla., June 16, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that Kelvin Cooper, Ph.D.
Lakewood-Amedex Stock Falls Despite Positive Nu-3 Manufacturing Update
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) shares were trading higher Monday but have since reversed and begun trading lower after the company announced data for Nu-3.
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers
Key formulation, delivery and manufacturing steps completed in preparation for planned Phase 2 clinical trial SARASOTA, Fla., May 18, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced positive data for its lead compound, Nu-3, as it advances towards a Phase 2 trial.
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listing SARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the appointment of Joseph Tucker, Ph.D.
Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"
/PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting,